The Biomedical Model in Psychopathology. A Critical Historical Outline, Contemporary Context and Ethical Problems

Main Article Content

Radosław Stupak
https://orcid.org/0000-0002-7318-546X

Abstract

The article presents a critical historical outline and description of the biomedical model of psychopathology, focusing on the second half of the 20th century. It also identifies and discusses the key problems connected with its dominance in the contemporary clinical and research practice. These problems concern, among other things, the validity and reliability of psychiatric diagnoses, research methodology, treatment effectiveness, or the influence of pharmaceutical companies on research and therapeutic activity. The serious conceptual problems of the whole model call into question the foundations and knowledge base of contemporary psychiatry. There are also justified doubts regarding antipsychotic and antidepressant medications nowadays – despite their increasingly wide use, the number of chronically ill people keeps rising. This situation leads to serious ethical problems and warrants questions regarding the over-medicalisation of issues commonly associated with mental health. A reform of research and clinical practice is urgent.

Downloads

Download data is not yet available.

Article Details

How to Cite
STUPAK, R. The Biomedical Model in Psychopathology. A Critical Historical Outline, Contemporary Context and Ethical Problems. Diametros, p. 1-18, 31 May 2020.
Section
Articles
Author Biography

Radosław Stupak

Institute of Philosophy

Grodzka 52
31-044 Kraków

e-mail: radek.stupak@doctoral.uj.edu.pl

 

Share |

References

Abbasi J. (2017), Ketamine Minus the Trip: New Hope for Treatment-Resistant Depression, „JAMA” 318 (20): 1964–1966.


DOI

Ahn R., Woodbridge A., Abraham A. et al. (2017), Financial Ties of Principal Investigators and Randomized Controlled Trial Outcomes: Cross Sectional Study, „BMJ” 356: i6770.


DOI

American Diabetes Association (2004), Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, „Diabetes Care” 27 (2): 596–601.


DOI

American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders. 4th ed., „APA”, Washington, DC.

Amsterdam J.D., McHenry L.B., Jureidini J.N. (2017), Zjawisko korupcji w badaniach psychia- trycznych, „Psychiatria Polska” 51 (6): 993–1008.


DOI

Bentall R.P. (2003), Madness Explained: Psychosis and Human Nature, Penguin, London. Bernstein F. (1970), A Ten-Year History of the Early Clinical Drug Evaluation Unit (ECDEU) Program, „Psychopharmacol Bulletin” 6: 1–21.

Bielefeldt A.Ø., Danborg P.B., Gøtzsche P.C. (2016), Precursors to Suicidality and Violence on Antidepressants: Systematic Review of Trials in Adult Healthy Volunteers, „JRSM” 109 (10): 381–392.


DOI

Blashfield R.K., Keeley J.W., Flanagan E.H. et al. (2014), The Cycle of Classification: DSM-I Through DSM-5, „Annual Review of Clinical Psychology” 10 (1): 25–51.


DOI

Bond C.H. (1914), The Position of Psychiatry and the Role of the General Hospitals in Its Improvement, „The Lancet” 184 (4755): 935–940.


DOI

Bracken P., Thomas P. (2001), Postpsychiatry: A New Direction for Mental Health, „BMJ” 322 (7288): 724–727.


DOI

Calton T., Ferriter M., Huband N. et al. (2008), A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed with Schizophrenia, „Schizophrenia Bulletin” 34 (1): 181–192.


DOI

Cosgrove L., Karter J.M. (2018), The Poison in the Cure: Neoliberalism and Contemporary Movements in Mental Health, „Theory & Psychology” 28 (5): 669–683.


DOI

Cowen P.J., Browning M. (2015), What Has Serotonin to Do with Depression?, „World Psychiatry” 14 (2): 158–160.


DOI

Davies J. (2017), How Voting and Consensus Created the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), „Anthropology & Medicine” 24 (1): 32–46.


DOI

Davies J., Read J. (2018), A Systematic Review into the Incidence, Severity and Duration of Anti- depressant Withdrawal Effects: Are Guidelines Evidence-Based?, „Addictive Behaviors” 97 (Oct 2019): 111–121.


DOI

de Barbaro B. (2014), Dylemat psychiatrii: „zły czy szalony”, „Psychiatra” 5 (7): 14–15.

Deacon B.J. (2013), The Biomedical Model of Mental Disorder: A Critical Analysis of Its Validity, Utility, and Effects on Psychotherapy Research, „Clinical Psychology Review” 33: 846–861.


DOI

Dell’Osso L., Pini S. (2012), What Did We Learn from Research on Comorbidity in Psychiatry? Advantages and Limitations in the Forthcoming DSM-V Era, „Clinical Practice and Epidemiology in Mental Health” 8: 180–184.


DOI

Dub L.A., Lurie L.A. (1939), Use of Benzedrine in the Depressed Phase of the Psychotic State, „Ohio State Medical Journal” 35: 39–45.

Dyga K., Stupak R. (2014), Obraz rehabilitacji psychiatrycznej w Polsce. Opis, porównania i ocena, [w:] Przepis na rehabilitację. Metodologie oraz metody w badaniach i transdyscyplinarnej praktyce rehabilitacyjnej, W. Otrębski, G. Wiącek (red.), Wydawnictwo KUL, Lublin.

Eichenwald K., Kolata G. (1999), A Doctor’s Drug Studies Turn into Fraud, URL = https://partners.nytimes.com/library/national/science/health/051799drug-trials-industry.html [dostęp 1.08.2016].

Ellenberger H.F. (1970), The Discovery of the Unconscious: The History and Evolution of Dynamic Psychiatry, Basic Books, New York, NY.

Fava G.A., Offidani E. (2011), The Mechanisms of Tolerance in Antidepressant Action, „Progress in Neuro-Psychopharmacology & Biological Psychiatry” 35 (7): 1593–1602.


DOI

U.S. Food and Drug Administration (2019), FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available Only at a Certified Doctor’s Office or Clinic, URL = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm632761.htm [dostęp 23.03.2019].

Frances A.J. (2012), DSM-5 Field Trials Discredit APA, URL = https://www.psychologyto-day.com/blog/dsm5-in-distress/201210/dsm-5-field-trials-discredit-apa [dostęp

02.2017].

Freemantle N., Anderson I.M., Young P. (2000), Predictive Value of Pharmacological Activity for the Relative Efficacy of Antidepressant Drugs: Meta-Regression Analysis, „The British Journal of Psychiatry” 177: 292–302.


DOI

Gøtzsche P. (2015), Deadly Psychiatry and Organised Denial, People’s Press, Copenhagen.

Harrow M., Jobe T.H., Faull R.N. (2012), Do All Schizophrenia Patients Need Antipsychotic Treatment Continuously Throughout Their Life Time? A 20-Year Longitudinal Study, „Psychological Medicine” 42 (10): 2145–2155.


DOI

Harrow M., Jobe T.H., Faull R.N. et al. (2017), A 20-Year Multi-Followup Longitudinal Study Assessing Whether Antipsychotic Medications Contribute to Work Functioning in Schizophrenia, „Psychiatry Research” 256: 267–274.


DOI

Healy D. (2002), The Creation of Psychopharmacology, Harvard University Press, Cambridge, MA.


DOI

Hoffer A., Osmond H., Smythies J. (1954), Schizophrenia: A New Approach. II. Results of a Year’s Research, „Journal of Mental Science” 100 (418): 29–45.

Ho B.-C., Andreasen N.C., Ziebell S. et al. (2011), Long-Term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia, „Archives of General Psychiatry” 68 (2): 128–137.


DOI

Hollister L. (1998), From Hypertension to Psychopharmacology: A Serendipitous Career, [w:] The

Psychopharmacologists, t. 2, D. Healy (red.), Chapman & Hall, London: 215–236.

Huston P., Moher D. (1996), Redundancy, Disaggregation, and the Integrity of Medical Research, „Lancet” 347: 1024–1026.


DOI

Insel T.R. (2006), Mental Illness and Brain Disease: Dispelling Myths and Promoting Recovery Through Awareness and Treatment. Subcommittee on Health of the Committee on Energy and Commerce, United States House of Representatives, URL = https://www.gpo.gov/fd-sys/pkg/CHRG-109hhrg30414/html/CHRG-109hhrg30414.htm [dostęp 10.06.2018].

Insel T.R. (2006b), NIMH’s Dr. Thomas Insel: Group Advocacy, More Data, Will Improve Eating

Disorders Research Funding, „Eating Disorders Review” 18: 5–6. Insel T.R. (2010), Faulty circuits, „Scientific American” 302: 44–51.

Insel T.R. (2013), Transforming Diagnosis, URL = https://www.nimh.nih.gov/about/directors/thomasinsel/blog/2013/transforming-diagnosis.shtml [dostęp 26.01.2017].

Jääskeläinen E., Juola P., Hirvonen N. et al. (2013), A Systematic Review and Meta-Analysis of Recovery in Schizophrenia, „Schizophrenia Bulletin” 39 (6): 1296–1306.


DOI

Jansen K.L.R. (2004), Ketamine: Dreams and Realities, Multidisciplinary Association for Psychedelic Studies, Sarasota, FL.

Kaczmarek E. (2018), How to Distinguish Medicalization from Over-Medicalization?, „Medicine, Health Care and Philosophy” 22 (1): 119–128


DOI

Kamenov K., Twomey C., Cabello M. et al. (2017), The Efficacy of Psychotherapy, Pharmacotherapy and Their Combination on Functioning and Quality of Life in Depression: A Meta-Analysis, „Psychological Medicine” 47 (3): 414–425.


DOI

Kamens S.R., Robbins B.D., Flanagan E.H. (2017), Introduction to the Special Issues on Diagnostic Alternatives, „Journal of Humanistic Psychology” 57 (6): 567–572.


DOI

Kinderman P. (2014), A Prescription for Psychiatry, Palgrave Macmillan, Basingstoke, Hampshire. Kirkpatrick B., Buchanan R.W., Ross D.E. et al. (2001), A Separate Disease Within the Syndrome of Schizophrenia, „Archives of General Psychiatry” 58 (2): 165–171.

Kirsch I., Deacon B.J., Huedo-Medina T.B. et al. (2008), Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration, „PLoS Med” 5 (2): e45.


DOI

Kirsch I., Huedo-Medina T.B., Pigott H.E. et al. (2018), Do Outcomes of Clinical Trials Resemble Those “Real World” Patients? A Reanalysis of the STAR*D Antidepressant Data Set, „Psychology of Consciousness: Theory, Research, and Practice” 5 (4): 339–345.


DOI

Krupitsky E.M., Grinenko A.Y. (1997), Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research, „Journal of Psychoactive Drugs” 29 (2): 165–183.


DOI

Leo J. (2018), Memo to the Newest Generation of Gene Hunters: Read Jay Joseph, „Psychosis” 10 (1): 58–61.


DOI

Longden E. (2013), The Voices in My Head. TED Talk, URL = https://www.ted.com/talks/eleanor_longden_the_voices_in_my_head?language=en [dostęp 11.08.2016].

Ludwig A.M. (1975), The Psychiatrist as Physician, „JAMA” 234 (6): 603–604.


DOI

Mithoefer M.C., Wagner M.T., Mithoefer A.T. et al. (2011), The Safety and Efficacy of {+/-}3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study, „Journal of Psychopharmacology” 25 (4): 439–452.


DOI

Mithoefer M.C., Mithoefer A.T., Feduccia A.A. et al. (2018), 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial, „Lancet Psychiatry” 5 (6): 486–497.


DOI

Moncrieff J. (2008), The Myth of the Chemical Cure, Palgrave Macmillan, Basingstoke, Hampshire.


DOI

Moncrieff J. (2008b), Neoliberalism and Biopsychiatry: A Marriage of Convenience, [w:] Liberatory Psychiatry: Philosophy, Politics, and Mental Health, C.I. Cohen, S. Timimi (red.), Cambridge University Press, New York, NY.

Moncrieff J., Kirsch I. (2015), Empirically Derived Criteria Cast Doubt on the Clinical Significance of Antidepressant-Placebo Differences, „Contemporary Clinical Trials” 43: 60–62.


DOI

Moncrieff J. (2016), Misrepresenting Harms in Antidepressant Trials, „BMJ” 352: i217. Moncrieff J. (2016b), New Research into Antipsychotic Discontinuation and Reduction: The RADAR programme, URL = https://joannamoncrieff.com/2016/03/02/new-research-into-antipsychotic-discontinuation-and-reduction-the-radar-programme/ [dostęp 10.06.2018].


DOI

Mulder R.T., Frampton C.M. (2013), Outcome of Mood Disorders Before Psychopharmacology: A Systematic Review, „Australian and New Zealand Journal of Psychiatry” 48 (3): 224–236.


DOI

Oronowicz-Jaśkowiak W., Bąbel P. (2019), Twenty Years After ‘Listening to Prozac but Hearing Placebo’. Do We Hear Placebo Even Louder?, „Health Psychology Report” 7 (1): 1–8. Pużyński S. (2014), Czy kryzys, „Psychiatra” 5 (7): 6–8.

Read J., Bentall R.P., Fosse R. (2009), Time to Abandon the Bio-Bio-Bio Model of Psychosis: Exploring the Epigenetic and Psychological Mechanisms by Which Adverse Life Events Lead to Psychotic Symptoms, „Epidemiology and Psychiatric Sciences” 18 (4): 299–310.


DOI

Rees W.L., King G.N. (1952), Cortisone in the Treatment of Schizophrenia, „The Journal of Mental Science” 98: 408–413.


DOI

Richardson T., Elliott P., Roberts R. et al. (2017), A Longitudinal Study of Financial Difficulties and Mental Health in a National Sample of British Undergraduate Students, „Community Mental Health Journal” 53 (3): 344–352.


DOI

Rogers A., Pilgrim D. (2001), Mental Health Policy in Britain, Palgrave Macmillan, Basingstoke, Hampshire.


DOI

Rogers D. (2017), Star Neuroscientist Tom Insel Leaves the Google-Spawned Verily for... A Startup?, URL = https://www.wired.com/2017/05/star-neuroscientist-tom-insel-leaves-google-spawned-verily-startup/ [dostęp 10.06.2018].

Rzewuska M. (2007), Zaburzenia metaboliczne związane ze stosowaniem leków przeciwpsychotycznych u chorych na schizofrenię, „Psychiatria Polska” 41 (4): 457–472.

Sarchet P. (2011), Harvard Scientists Disciplined for Not Declaring Ties to Drug Companies, URL = http://blogs.nature.com/news/2011/07/harvard_scientists_disciplined.html [dostęp 30.10.2018].

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014), Biological Insights from 108 Schizophrenia-Associated Genetic Loci, „Nature” 511 (7510): 421–427.


DOI

Scull A. (1994), Somatic Treatments and the Historiography of Psychiatry, „Historiography of Psychiatry” 5: 1–12.


DOI

Seikkula J., Alakare B., Aaltonen J. et al. (2006), 5 Years Experiences of First-Episode Non-Affective Psychosis in Open Dialogue Approach: Treatment Principles, Follow-Up Outcomes and Two Case Analyses, „Psychotherapy Research” 16: 214–228.


DOI

Sharma T., Guski L.S., Freund N. et al. (2016), Suicidality and Aggression During Antidepressant Treatment: Systematic Review and Meta-Analyses Based on Clinical Study Reports, „BMJ” 352: i65.


DOI

Shorter E. (2005), Historia psychiatrii. Od zakładu dla obłąkanych po erę Prozacu, tłum. P. Turski, Wydawnictwa Szkolne i Pedagogiczne, Warszawa.

Smith R. (2005), Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies, „PLoS Med” 2 (5): e138.


DOI

Spielmans G.I., Parry P.I. (2010), From Evidence-Based Medicine to Marketing-Based Medicine: Evidence from Internal Industry Documents, „Journal of Bioethical Inquiry” 7 (1): 13–29.


DOI

Stupak R., Dobroczyński B. (2019), Projekt Soteria: zwiastun „trzeciej drogi” w psychiatrii?, „Psychiatria Polska” 53 (6): 1351–1364.


DOI

Stupak R., Dyga K. (2018), Postpsychiatry and Postmodern Psychotherapy: Theoretical and Ethical Issues in Mental Health Care in a Polish Context, „Theory & Psychology” 28 (6): 780–799.


DOI

Thacker P.D. (2018), Time to Act on Industry Influence Over Medicine and Lay Zombie Arguments to Rest, URL = https://blogs.bmj.com/bmj/2018/10/05/paul-d-thacker-time-to-act-on-industry-influence-over-medicine-and-lay-zombie-arguments-to-rest/ [dostęp 30.10.2018].

The Brainstorm Consortium (2018), Analysis of Shared Heritability in Common Disorders of the Brain, „Science” 360 (6395): eaap8757.

Varese F., Smeets F., Drukker M. et al. (2012), Childhood Adversities Increase the Risk of Psychosis: A Meta-Analysis of Patient-Control, Prospective and Cross-Sectional Cohort Studies, „Schizophrenia Bulletin” 38 (4): 661–671.


DOI

Veling W., Susser E., van Os J. et al. (2008), Ethnic Density of Neighborhoods and Incidence of Psychotic Disorders Among Immigrants, „The American Journal of Psychiatry” 165 (1): 66–73.


DOI

Waszkiewicz A.A., Nizio A.M. (2014), Rola psychologa klinicznego w szpitalu psychiatrycznym, „Psychiatria i Psychoterapia” 10 (1): 3–10.

Whitaker R. (2002), Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill, Perseus Publishing, Cambridge, MA.

Whitaker R. (2016), The Case Against Antipsychotics: A Review of Their Long-Term Effects, URL = http://www.madinamerica.com/wp-content/uploads/2016/07/The-CaseA-gainst-Antipsychotics.pdf [dostęp 10.08.2016].

Whiteford H.A., Harris M.G., McKeon G. et al. (2013), Estimating Remission from Untreated Major Depression: A Systematic Review and Meta-Analysis, „ Psychological Medicine” 43 (8): 1569–1585.


DOI

Wicks S., Hjern A., Dalman C. (2010), Social Risk or Genetic Liability for Psychosis? A Study of Children Born in Sweden and Reared by Adoptive Parents, „The American Journal of Psychiatry” 167 (10): 1240–1246.


DOI

Williams J.B., Gibbon M., First M.B. et al. (1992), The Structured Clinical Interview for DSM- III-R (SCID): II. Multisite Test–Retest Reliability, „Archives of General Psychiatry” 49 (8): 630–636.


DOI

Wolfers T., Doan N.T., Kaufmann T. et al. (2018), Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models, „JAMA Psychiatry” 75 (11): 1146–1155.


DOI

Wunderink L., Nieboer R.M., Wiersma D. et al. (2013), Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-Up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-Term Follow-Up of a 2-Year Randomized Clinical Trial, „JAMA Psychiatry” 70 (9): 913–920.


DOI

Yesavage J.A., Fairchild J.K., Mi Z. et al. (2018), Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial, „JAMA Psychiatry” 75 (9): 884–893.


DOI